Estrogen alone decreased, while adding progestin increased, breast cancer incidence SAN ANTONIO — Long-term follow-up results from two large,...
Hahn has shown a commitment to science-directed and patient-focused policies PHILADELPHIA — The American Association for Cancer Research (AACR),...
SAN ANTONIO — Among women with hormone receptor (HR)-positive, HER2-negative breast cancer with a high clinical risk (determined by tumor...
SAN ANTONIO — The addition of the anti-PD-L1 immunotherapeutic atezolizumab (Tecentriq) to neoadjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) did...
SAN ANTONIO — Breast cancer incidence among postmenopausal women at high risk for developing the disease continued to be...
10-year follow-up data supports earlier findings on recurrence and survival SAN ANTONIO — A 10-year follow-up study of breast...
SAN ANTONIO — The addition of the anti-PD-1 immunotherapeutic pembrolizumab (Keytruda) to neoadjuvant chemotherapy increased the rates of pathologic complete response (pCR)...
SAN ANTONIO — Neoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response...
SAN ANTONIO — The investigational HER2-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) demonstrated durable objective responses in patients with...
SAN ANTONIO — Data from six-year analysis of the APHINITY trial showed that adding pertuzumab to the previous standard of trastuzumab...